Ignite Creation Date:
2024-05-06 @ 2:06 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04210115
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-12
First Post:
2019-12-20
Brief Title:
Study of Pembrolizumab MK-3475 Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy MK-3475-975KEYNOTE-975
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC